European Archives - Page 1495 of 1573 - European Medical Journal

Immune checkpoint inhibitors and biomarker-driven strategies for managing lung cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen…

An update on the treatment of chronic lymphocytic leukaemia

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Stephan Stilgenbauer, MD, of Ulm University, Ulm, Germany, reviews the changing…

HELIOS: Phase 3 trial of ibrutinib with bendamustine and rituximab for relapsed/refractory CLL

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of North Shore-LIJ Cancer Institute, Lake Success, NY…

IMAAGEN: Phase 2 trial of abiraterone acetate for advanced prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, provides…

CheckMate 067: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale…

The evolving role of chemotherapy for the management of advanced prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Villejuif, France…

Daratumumab for heavily pretreated multiple myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta…

Current clinical perspectives on targeted therapy and immunotherapy for melanoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif, France…

ENDEAVOR: Phase 3 trial comparing carfilzomib versus bortezomib in relapsed multiple myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the…

Phase 2 trial of lenvatinib and everolimus for metastatic renal cell carcinoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA…